
Prosjekt vi støtter
Her kan du lese mer om den forskningen som vi og våre søster-stiftelser i Sverige og Finland har vært med på å finansiere siden starten i 2008. Vi støtter både forskning innenfor diabetes typ1 og diabetes type 2.
Diabetes Wellness søker aktivt etter prosjekter som antas å ha de beste forutsetninger for å utvikle forbedrede behandlingsmåter eller å komme nærmere en endelig kur for diabetes.
Vår rådgivende komité vurderer mottatte søknader og gir sin anbefaling til styret, som fatter den endelige beslutningen.
Siden starten har Diabetes Wellness Sverige finansiert forskning for nærmere 100 millioner kroner, takket være de gavmilde menneskene som har valgt å støtte vårt arbeide.
Diabetes Wellness Norge er fortsatt relativt ung, og vi arbeider med å etablere en stabil base med støttespillere som kan hjelpe oss å finansiere forskning, både i Norge og utlandet.
Inntil videre kan du lese om noen av de prosjektene som vår svenske søsterorganisasjon har støttet.
Vil du være med og støtte forskningen?
Gjennom å støtte Diabetes Wellness Norge hjelper du oss i kampen mot diabetes. Din støtte bidrar ikke bare til å finansiere forskning på diabetes, men også til å informere allmennheten om sykdommen og dens mange farlige komplikasjoner.
Du hjelper oss ved å betale inn et valgfritt beløp til vår bankkonto 9046 12 86215. Husk at alle beløp er til nytte, og at ingen gave er for liten.
2020
Dr Olof Eriksson, Uppsala Universitet
1 303 200 SEK
GPR44 as a PET marker for measuring beta cell mass in human.
Professor Patrik Rorsman, Göteborgs Universitet
2 000 000 SEK
Pathophysiologycaemia risk in insulin-treated diabetes patients:more than the sum of the parts? Typ 1 diabetes.
Professor Anders Tengholm, Uppsala Universitet
2 000 000 SEK
Rap and Ras signalling in insulin secretion.
Dr Ingrid Wernstedt Asterholm, Göteborgs Universitet
2 000 000 SEK
Succinate-induced glucose uptake in skeletal muscle - a new therapeutic target for diabetes?
2017
Dr. Mototsugu Nagao, Lunds Universitet
200 000 SEK
CD36 as a therapeutic target to improve beta cell function in type 2 diabetes
Dr. Oskar Skog, Uppsala Universitet
200 000 SEK
Characerization of the diabetic pancreas to unravel the pathogenesis and etiology of type 1 diabetes
Dr. Andreas Edsfeldt, Lunds Universitet
200 000 SEK
Diabetes associated vascular complications caused by impaired efferocytosis, inflammatory resolution and fibrotic tissue repair
Professor Nils Wierup, Lunds University
2 000 000 SEK
Discovery and functional validation of regulatory networks in human pancreatic islets to identify targetable disease mechanisms underlying Type 2 diabetes
Dr. Emma Ahlqvist, Lund University
1 981 000 SEK
How many diseases are type 2 diabetes? Confirmation, evaluation and implementation of a new diabetes subclassification
Dr. Evelina Vågesjö, Uppsala University
200 000 SEK
Mechanisms in skin wound healing in non-diabetic and diabetic conditions and the effect of wound treatment with chemokines
Professor Lena Eliasson, Lund University
2 000 000 SEK
Novel therapeutic tools and new biomarkers in diabetes with focus on islet specifik microRNAs
Dr Bernard Hering, University of Minnesota
850 000 SEK
Refining Immunosuppression to Prevent Rejection of Porcine Islet Xenografts
Dr. Abdul Waheed Khan, Karolinska Institutet
200 000 SEK
Role of acetyltransferase GCN5 in endothelial oxidative stress in diabetes
Professor Per-Ola Carlsson, Uppsala University
2 000 000 SEK
Translational studies of insulinsecreting cells derived from induced pluripotent stem cells
Dr Bernard Hering, University of Minnesota, Diabetes Institute for Immunology and Transplantation
167 000 USD
Spring Point Project, its mission is to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes
2016
Dr Anna Nordström, Umeå universitet
1 000 000 SEK
6000 steps for better health – a randomised 12-month intervention study
Dr Anya Medina Benavente, Lunds Universitet
200 000 SEK
Autophagy in control of beta-cell mass and function in Type 2 Diabetes
Dr Luis Sarmiento, Lunds Universitet
200 000 SEK
Communication between virus-infected pancreatic beta-cells and the immune system: implication for Type 1 diabetes
Dr Jennifer Jager, Karolinska Institutet
200 000 SEK
Contribution of genes and non-coding RNAs expressed by Kupffer cells in insulin resistance
Professor Fredrik Bäckhed, Göteborgs universitet
2 000 000 SEK
Determining the microbiota in subjects with prediabetes
Dr Joan Domingo-Espin, Lunds universitet
200 000 SEK
Does Glycation of apoA-I links to higher risk of cardiovascular complications in diabetic patients?
Dr Midhat Abdulreda, Diabetes Research Institute Miami University
900 000 SEK
In collaboration with Prof. PO Berggren, Karolinska Institutet: Evaluating vision in the baboon following pancreatic islet transplantation in the eye anterior chamber
Dr Rashmi Prasad Bokkasa, Lunds universitet
200 000 SEK
Genetic and transcriptomic studies of fetal pancreas to understand fetal programming and development and identification of blood based biomarkers for pancreatic development
Professor Erik Renström, Lunds universitet
1 983 349 SEK
Growth differentiation factor 11 (GDF11) – a fons adolescentia for the pancreatic beta-cell that can delay or prevent onset of type 2 diabetes?
Dr Olof Lagerlöf, Karolinska Institutet
1 938 350 SEK
Molecular control over a neuronal circuit that mediates feeding behaviour – and important new target in the fight against diabetes
Dr Bernard Hering, University of Minnesota
850 000 SEK
Refining Immunosuppression to Prevent Rejection of Porcine Islet Xenografts
Professor Eva Degerman, Lunds Universitet
346 000 SEK
Short chain fatty acids; gut metabolites with implications for metabolic health
Professor John Pernow, Karolinska Institutet
1 000 000 SEK
The importance of endothelial and red blood cell dysfunction for vascular complications in type 2 diabetes
Professor Olle Korsgren, Uppsala universitet
1 800 000 SEK
The role of the duodenal microbiota in the etiopathology of Type 1 Diabetes
Dr Bernard Hering, University of Minnesota, Diabetes Institute for Immunology and Transplantation
167 000 USD
Spring Point Project, its mission is to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes
2015
Per-Olof Berggren, Karolinska Institutet
2 000 000 SEK
An in vivo approach to understand inositide signalling in the pancreatic beta cell
Anders Tengholm, Uppsala Universitet
1 000 000 SEK
Betydelsen av budbärarämnet cAMP för reglering av insulin- och glukagonfrisättningen
Peetra Magnusson, Uppsala Universitet
250 000 SEK
Cellular interactions of mesenchymal stromal cells in type 1 diabetes
Karin Stenkula, Lunds Univeristet
250 000 SEK
Correlation between systemic insulin resistance and bimodal adipose cell response
Margit Mahlapuu, Göteborg universitet
925 000 SEK
En ny unik medicinsk behandling av typ-2 diabetes baserat på hämmandet av proteinkinaset STK25
Charlotte Ling, Lunds universitet
1 000 000 SEK
Hur påverkar fetma och typ 2 diabetes muskelstamcellernas funktion?
Olov Andersson, Karolinska Institutet
1 000 000 SEK
Novel strategies for treating diabetes
Mia Phillipson, Uppsala Universitet
1 002 000 SEK
The role of pancreatic macrophages for development and maturation of islets of Langerhans and long-term metabolic control
Dariush Mokhtari, Akademiska Sjukhuset Uppsala
250 000 SEK
Tissue factor signaling in islets and beta-cells
Juleen Zierath och Anna Krook, Karolinska Institutet
1 000 000 SEK
Träningsintervention vid metabola sjukdomar
Helena Edlund, Umeå Universitet
2 000 000 SEK
Typ 2 diabetes: en betacellsdegenerativ sjukdom?
Francesco Paneni, Karolinska Institutet
250 000 SEK
Understanding redox signalling in diabetic cardiomyopathy: role of AP-1 transcription factor JunD
Ola Hansson, Lunds universitet
1 000 000 SEK
Vilken påverkan har ärftlighet på muskelegenskaper och metabolsjukdom? - funktionen av RAB3GAP2 och MAOA
2014
Sebastian Barg, Uppsalas universitet
2 000 000 SEK (2015-2016)
Assembly of the insulin granule secretory machinery
Gunilla Westermark, Uppsalas universitet
240 000 SEK (2015)
Can high concentrations of IAPP in plasma indicate the formation of beta-cell toxic species?
Hindrik Mulder, Malmö
950 000 SEK (2015)
Dissecting the role of mitochondrial dysfunction in pancreatic beta-cells in Type 2 Diabetes
Nils Welsh, Uppsalas universitet
300 000 SEK (2015)
Does brusatol counteract high-fat diet-induced glucose intolerance in mice?
Karl Tryggvason, Karolinska Intstitutet
1 000 000 SEK (2015)
Expansion of pancreatic islets in vitro and transplantation treatment in diabetic mice
Nils Wierup, Lunds universitet
2 000 000 SEK (2015-2016)
Gastric bypass surgery as a model for identification of new treatments for Type 2 Diabetes
Ingrid Wernstedt Asterholm, Göteborgs universitet
300 000 SEK (2015)
Mechanisms underlying 'browning' of white adipose tissue
Luca Inverardi, M.D, Diabetes Research Institute in Miami
669 400 SEK
Myeloid-derived suppressor cells for tolerance to islet transplants
Isabella Artner, Lunds universitet
2 000 000 SEK (2015-2016)
Neural control of the endocrine pancreas - from molecular pathways to human physiology in health and disease
Ulf Ahlgren, Umeå universitet
683 000 SEK (2015)
Novel approaches for monitoring of endogenous ?-cells
Olle Korsgren, Uppsalas universitet
1 000 000 SEK (2015)
Quantitate imaging as a tool to characterize the ongoing pathophysiology in children with recent onset type 1 diabetes
Juleen Zierath, Karolinska Institutet
200 000 SEK
Targeted exercise intervention in the prevention of metabolic disease
Erik Renström, Lunds universitet
2 000 000 SEK (2015-2016)
The gamma-4 subunit of voltage-gated calcium ion channels (CaV?4) is an effector of beta-cell dedifferentiation in type 2 diabetes and a potential target for disease-modifying treatment
John Pernow, Karolinska Institutet
2 000 000 SEK (2015-2016)
The role of arginase as a novel therapeutic target to improve cardiovascular function in type 2 diabetes
Per-Ola Carlsson, Uppsalas Universitet
830 000 SEK (2015-2016)
Transplantation of human islets in oxygenated macrocapsules to patients with type 1 diabetes mellitus
2013
Leif Jansson, Uppsala universitet
1 320 000 SEK (2014-2015)
A systematic exploration of proteins for future site-targeted delivery of therapeutics to the native human islets
Daniel Nyqvist, Karolinska Institutet
300 000 SEK (2014)
Characterisation of VEGF-B as a regulator of pancreatic B-cell lipid handing and function
Jorge Lira Ruas, Karolinska Institutet
1 200 000 SEK (2014-2015)
Farnesoid X receptor isoforms and their roles in liver energy metabolism
Albert Salehi, Lunds universitet
1 320 000 SEK (2014-2015)
Insulin suppresses counterregulatory glucagon secretion by an indirect effect mediated by stimulation of somatostatin secretion from delta cells
Bryndis Birnir, Uppsala University
2 000 000 SEK (2014-2015)
Interstitial GABA regulates alpha, beta and delta cells in human islets
Jan Boren, University of Gothenburg
2 000 000 SEK (2014-2015)
Mechanisms for and consequences of ectopic lipid accumulation
Margit Mahlapuu, Göteborg universitet
400 000 SEK (2014)
Molecular mechanisms and treatment strategies of T2DM
Annika Rosengren, Sahlgrenska University Hospital
431 000 SEK (2014)
Normalizing risk of death and cardiovascular diseases in type 1 diabetes
Olle Korsgren, Uppsalas universitet
660 000 SEK (2014)
Rediscovery of the etiology of T1D in humans
Rayner Rodriguez-Diaz, Rolf Luft Centre for Diabetes Research
1 013 500 SEK (2014-2015)
Study of the neuroimmune synapse in the islet of Langerhans
Dr Bernard Hering, University of Minnesota
1 200 000 SEK (2014-2015)
Funding of this grant will help Spring Point Project achieve its mission to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes
2012
Ulf Ahlgren, Umeå universitet
850 000 SEK
A novel approach for non-invasive monitoring of endogenous beta-cells
Sebastian Barg, Uppsalas universitet
1 200 000 SEK för år 2013-2014
Characterization of proteins and drugs that effect insulin granule docking
Erik Renström, Lunds universitet
1 200 000 SEK för år 2013-2014
Drug Repositioning to Prevent Activity-Dependent Calcium Signals in Pancreatic Beta-cells and Type-2 Diabetes Progression
Lena Eliasson, Lunds universitet
1 200 000 SEK för år 2013-2014
GIP and ostepontin in islet cell function- can GIPR variants influence response to treatment in type-2 diabetes?
Per-Olof Berggren, Karolinska Institutet
400 000 SEK
In vivo imaging of functional pancreatic beta-cell mass
Hindrik Mulder, Lunds universitet
300 000 SEK
Islet metabolism and circadian rhythm
Mia Phillipson, Uppsala Universitet
440 000 SEK
Local bioengineering of muscle prior to islet transplantation to improve engraftment and induce immunological shielding
Per-Ola Carlsson, Uppsalas Universitet
1 200 000 SEK för år 2013-2014
Means to preserve and restore beta-cell mass in type 1 diabetes mellitus
Susanna Cardell, Göteborgs universitet
1 200 000 SEK för år 2013-2014
Mechanistic studies of a novel mucosal tolerance-inducing molecule that type-1 diabetes
Margit Mahlapuu, Göteborg universitet
300 000 SEK
Molecular mechanisms and treatment strategies of T2DM
2011
Per-Olof Berggren
276 000 SEK
Biomarkers for functional pancreatic beta-cell mass
Per-Anders Jansson, Sahlgrenska Universitetsjukhuset
518 000 SEK
Clinical and experimental studies of insulin resistance
Erik Ingelsson, Karolinska Institutet
518 000 SEK
Genetics of Insulin sensivity: An integrated approach to discovery
Hindrik Mulder, Lunds universitet
424 000 SEK
Islet metabolism circadian rhythm melatonin receptors and clock genes
Margit Mahlapuu, Sahlgrenska universitetssjukhus
518 000 SEK
Molcular mechanism and treatment strategies of Type-2 diabetes
Luca Inverardi, M.D, Diabetes Research Institute in Miami
700 000 SEK
Myeloid-derived suppressor cells for tolerance to islet transplants
Gun Frisk, Uppsalas universitet
341 000 SEK
Ongoing pathogenic processes in the pancreas at onset or prior to onset of Type 1 Diabetes in humans
Anna Krook, Karolinska Institutet
518 000 SEK
Regulation of skeletal muscle insulin resistance
Per-Ola Carlsson, Uppsalas universitet
621 000 SEK
Stem cell therapies to regenerate the endocrine pancreas in type 1 diabetes mellitus
Mikael Rydén, Karolinska Institutet
518 000 SEK
Transcription factors regulating insulin sensivity in human adipose tissue
Claes Wadelius, Uppsalas universitet
518 000 SEK
Translating genetic associations for Type-2 diabetes to biological processes using chromatin maps
2010
Professor Gwyn Gould, University of Glasgow
£20,000.00
Analysis of tethering factors in the regulation of Glut4 spatial dynamics
Dr Katarina Kos, Peninsula Medical School
£19,260.00
Are human SPARC isoforms suitable peripheral makers of insulin resistance and diabetes-related complications?
Cesare Patrone, Karolinska Institutet
525 000 SEK
GLP-1R activation for the treatment of stroke in diabetes
Daniel Brandhorst, Rudbeck Laboratory
945 000 SEK
Hybrid preservation fluids and modular enzyme systems: significant means to optimizehuman islet transplantation
Dr Catherine Arden, Newcastle University
£13,665.00
Investigation of the association between glucokinase and the pro-apoptotic protein BAD in pancreatic beta-cells
Dr Gaya Thanabalasingham, Oxford Centre for Diabetes
£19,211.40
Investigation of the incretin pathway in Maturity onset diabetes of the young (MODY) secondary to heterozygous hepatocyte nuclear factor 1 alpha (HNF1A) gene mutations
Per-Ola Carlsson, Uppsala Biomedicinska centrum, BMC
525 000 SEK
Mesenchymal Stem Cells for Treatment of Newly Onset Type 1 Diabetes
Dr Neil Reeves, Manchester Metropolitan University
£19,423.00
Peripheral neuropathy and muscle weakness: how do they influence the safety of daily gait tasks for people with diabetes?
Henrik Ortsäter, Karolinska Institutet
525 000 SEK
Protein phosphate 5 can protect pancreatic beta-cells against the diabetogenic propeties of glucocorticoids and a high-fat diet
Dr Lazaros Foukas, University College London
£19,662.00
Role of adipose tissue in age-dependent beneficial effects of PI 3-kinase pathway inactivation on glucose and lipid homeostasis
Dr Jeremy Turner, University of East Anglia
£9628.00
The regulation of metalloproteinases and tissue inhibitors of metalloproteinases in adipose inflammation and type2diabetes
The Spring Point Project in Minneapolis, University of Minnesota
$200 000 USD
Funding of this grant request will help Spring Point Project achieve its mission to provide an unlimited source of pig islet cells to accelerate the availability and affordability of islet transplantation to cure diabetes
2009
Åke Sjöholm, Karolinska Institutet
400 000 SEK
Exendin-4 protection of normal and diabetic human coronary artery endothelial cells in diabetic macroangiopathy
David Erlinge, Lunds universitetssjukhus
200 000 SEK
Extracellular nucleotide receptors as targets for the treatment of diabetes
Mrs Melanie Cope, DRWF Islet Isolation Facility Oxford UK
£27,696.00 GBP
Funding of Islet Transplant Administrator within the DRWF Islet Isolation Facility
Olle Korsgren, Rudbecklaboratoriet
500 000 SEK
Hybrid preservation fluids and modular enzyme systems: significant means to optimize human islet transplantation
2008
Olle Korsgren, Uppsalas universitet
200 000 SEK
Development of a protocol using LMW-DS and Compstatin to inhibit the IBMIR in xenogeneic islet transplantation
Åke Sjöholm, Karolinska Institutet
200 000 SEK
Exendin-4 protection of normal and diabetic human coronary artery endothelial cells in diabetic macroangiopathy
David Erlinge, Lunds universitetssjukhus
200 000 SEK
Extracellular nucleotide receptors as targets for the treatment of diabetes